Novel potassium binders to optimize RAASi therapy in heart failure: A systematic review and meta-analysis.

• The impact of hyperkalemia in the down-titration or reduction of HF therapy is well known. • Patiromer and sodium zirconium cyclosilicate are new treatment available for hyperkalemia. • Patiromer and sodium zirconium cyclosilicate were significantly associated with heart failure therapy optimization, reduction of hyperkalemia events and reduction of mean potassium levels, albeit with a higher rate of hypokalemia events. • Trials evaluating whether this heart failure therapy optimization results in a lower incidence of major adverse cardiovascular events are now needed. Hyperkalemia often occurs among heart failure (HF) patients, particularly when treated with renin-angiotensin-aldosterone system inhibitors (RAASi). Even modest potassium levels variations raise the risk of mortality and prompt patients to discontinue disease-modifying treatment, as RAASi. Novel potassium binders (NPB), patiromer and sodium zirconium cyclosilicate, are effective in reducing potassium levels and are approved for the treatment of hyperkalemia in HF, but whether their use results in a real optimization of HF treatment remains to be seen. The aim of the present meta-analysis was to assess the efficacy of NPB on the optimization of RAASi therapy in HF patients. PubMed, Web of Science and Clinicaltrial.gov were searched without restrictions from inception to 06 August 2022 to identify valuable articles. The studies that met the inclusion criteria were analyzed. The prespecified primary outcome was the optimization of RAASi therapy in HF patients, defined as the proportion of patients on RAASi at the end of follow-up. Secondary outcomes were hyperkalemia events, reduction in potassium levels, and adverse drugs reactions. Six studies with a total of 1390 patients were included. NPB improved RAASi therapy optimization in HF by 14% (95% CI: 4–26%), decreased hyperkalemia events by 29% (95% CI: 55–92%), and reduced potassium levels by 0.31 mEq/L (95% CI: 0.18–0.44) compared to placebo, maintaining a good safety profile. NPB are effective in allowing RAASi therapy optimization in patients affected by HF, in reducing hyperkalemia events and potassium levels. CRD42022351811 URL: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=351811 NPB in HF: A new therapeutic approach for an old problem Caption: CI, confidence interval; GI, gastrointestinal; HF, heart failure; NPB, novel potassium binders; RAASi, RAAS inhibitors; RCT, randomized controlled trial; RR, relative risk; SZC, sodium zirconium cyclosilicate. [Display omitted] [ABSTRACT FROM AUTHOR]